These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33130696)

  • 1. [Assessment of Efficacy and Adverse Effects of Trastuzumab Biosimilar in Gastric Cancer].
    Okuda Y; Mikame Y; Shinada M; Yamaguchi H; Fujii H; Sudoh T
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1341-1344. PubMed ID: 33130696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Trastuzumab Biosimilar (CT-P6) Compared With Reference Trastuzumab in Patients With HER2-positive Advanced Gastric Cancer: A Retrospective Analysis.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Cho EK; Shin DB; Yang JY; Kim HS; Lee WK; Sym SJ
    Am J Clin Oncol; 2022 Feb; 45(2):61-65. PubMed ID: 34991106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABP 980: A Trastuzumab Biosimilar.
    Dhillon S
    BioDrugs; 2018 Oct; 32(5):511-514. PubMed ID: 30264234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and Safety of Trastuzumab Biosimilars in Combination with Pertuzumab].
    Shinada M; Okuda Y; Mikame Y; Kezuka C; Suga R; Saitou T; Kobayashi N; Hoshi C; Imai Y
    Gan To Kagaku Ryoho; 2023 May; 50(5):615-618. PubMed ID: 37218323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union.
    Wyrwicz L; Rodríguez Sánchez CA; Sánchez-Rovira P; Lewis S; Sandschafer D; San T
    Future Oncol; 2024 Apr; 20(13):821-832. PubMed ID: 38305004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the trastuzumab biosimilar candidate CT-P6.
    Esteva FJ; Saeki T; Kim H; Stebbing J
    Future Oncol; 2018 Aug; 14(19):1909-1919. PubMed ID: 29482364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative phase III clinical study to evaluate efficacy and safety of TrastuRel™ (biosimilar trastuzumab) and innovator trastuzumab in patients with metastatic human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
    Apsangikar P; Chaudhry S; Naik M; Deoghare S; Joseph J
    Indian J Cancer; 2017; 54(4):664-668. PubMed ID: 30082554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.
    Paplomata E; Nahta R
    Expert Opin Biol Ther; 2018 Mar; 18(3):335-341. PubMed ID: 29350568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion Reactions in HER2-Positive Gastric Cancer: Switching from Trastuzumab to Its Biosimilar.
    Abe T; Sagara A; Suzuki T; Okada D; Matsuzaka K; Nakayama T
    Biol Pharm Bull; 2024; 47(8):1452-1455. PubMed ID: 39168631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SB3 (Ontruzant
    Lamb YN
    BioDrugs; 2018 Jun; 32(3):293-296. PubMed ID: 29796993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance study.
    Park MH; Seo JH; Park JH; Seong MK; Park KU; Kim MK; Chang M; Koh SJ; Lee MH; Lim ST; Yoo YB; Oh SY; Kim SH; Ahn KY; Park TH; Ju H; Baek EH; Kim S; Kim N; Lee E; Kim TH
    Expert Opin Biol Ther; 2024 Apr; 24(4):305-312. PubMed ID: 38664937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
    Jeon C; Kang SH; Kim SB; Paik NS; Lee I; Kim SK; Kim EY; Son GS; Yoo YB; Lee KH; Shin J; Ju S; Jang H; Park MH
    Oncology; 2024; 102(6):465-475. PubMed ID: 37899039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PF-05280014: A Trastuzumab Biosimilar.
    Paik J
    BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biosimilars in oncology. Focus on SB3 studies.].
    Del Re M; Del Mastro L
    Recenti Prog Med; 2018 Nov; 109(11):531-539. PubMed ID: 30565572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trastuzumab and its biosimilars].
    Sarosiek T; Morawski P
    Pol Merkur Lekarski; 2018 May; 44(263):253-257. PubMed ID: 29813044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Appropriate use of trastuzumab in Lazio Region: therapeutic scenarios and estimation of possible savings for the Regional Health Service.].
    Belleudi V; Rosa AC; Musicco F; Marchetti P; Martini N; Andriani A; Calamia T; Addis A
    Recenti Prog Med; 2019 Dec; 110(12):604-614. PubMed ID: 31909763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
    Pivot X; Bondarenko I; Nowecki Z; Dvorkin M; Trishkina E; Ahn JH; Vinnyk Y; Im SA; Sarosiek T; Chatterjee S; Wojtukiewicz MZ; Moiseyenko V; Shparyk Y; Bello M; Semiglazov V; Song S; Lim J
    J Clin Oncol; 2018 Apr; 36(10):968-974. PubMed ID: 29373094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Important Step Forward for Biosimilars in Cancer Treatment.
    Schleicher SM; Seidman AD
    JAMA Oncol; 2017 Jul; 3(7):989-990. PubMed ID: 28196209
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.